Logo image of BMGL

BASEL MEDICAL GROUP LTD (BMGL) Stock Fundamental Analysis

NASDAQ:BMGL - Nasdaq - VGG0864B1031 - Common Stock - Currency: USD

3.46  -1.24 (-26.38%)

After market: 3.76 +0.3 (+8.67%)

Fundamental Rating

5

BMGL gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 102 industry peers in the Health Care Providers & Services industry. BMGL has an excellent financial health rating, but there are some minor concerns on its profitability. BMGL is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

BMGL had positive earnings in the past year.
BMGL had a positive operating cash flow in the past year.
BMGL Yearly Net Income VS EBIT VS OCF VS FCFBMGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 2024 1M 2M 3M 4M

1.2 Ratios

BMGL has a better Return On Assets (12.71%) than 95.10% of its industry peers.
With an excellent Return On Equity value of 27.41%, BMGL belongs to the best of the industry, outperforming 93.14% of the companies in the same industry.
With an excellent Return On Invested Capital value of 31.78%, BMGL belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for BMGL is significantly above the industry average of 9.62%.
The 3 year average ROIC (29.84%) for BMGL is below the current ROIC(31.78%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 12.71%
ROE 27.41%
ROIC 31.78%
ROA(3y)12.01%
ROA(5y)N/A
ROE(3y)37.76%
ROE(5y)N/A
ROIC(3y)29.84%
ROIC(5y)N/A
BMGL Yearly ROA, ROE, ROICBMGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 2024 10 20 30 40 50

1.3 Margins

BMGL's Profit Margin of 20.62% is amongst the best of the industry. BMGL outperforms 99.02% of its industry peers.
BMGL has a better Operating Margin (44.01%) than 100.00% of its industry peers.
Industry RankSector Rank
OM 44.01%
PM (TTM) 20.62%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BMGL Yearly Profit, Operating, Gross MarginsBMGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 2024 10 20 30 40

More info and screens

9

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), BMGL is creating value.
BMGL has about the same amout of shares outstanding than it did 1 year ago.
The debt/assets ratio for BMGL has been reduced compared to a year ago.
BMGL Yearly Shares OutstandingBMGL Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 2024 5M 10M 15M
BMGL Yearly Total Debt VS Total AssetsBMGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 2024 5M 10M 15M

2.2 Solvency

BMGL has an Altman-Z score of 6.45. This indicates that BMGL is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 6.45, BMGL belongs to the best of the industry, outperforming 91.18% of the companies in the same industry.
The Debt to FCF ratio of BMGL is 1.71, which is an excellent value as it means it would take BMGL, only 1.71 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 1.71, BMGL belongs to the best of the industry, outperforming 83.33% of the companies in the same industry.
A Debt/Equity ratio of 0.56 indicates that BMGL is somewhat dependend on debt financing.
BMGL has a Debt to Equity ratio (0.56) which is comparable to the rest of the industry.
Even though the debt/equity ratio score it not favorable for BMGL, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF 1.71
Altman-Z 6.45
ROIC/WACC3.73
WACC8.53%
BMGL Yearly LT Debt VS Equity VS FCFBMGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 2024 2M 4M 6M

2.3 Liquidity

BMGL has a Current Ratio of 2.26. This indicates that BMGL is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.26, BMGL is in the better half of the industry, outperforming 79.41% of the companies in the same industry.
A Quick Ratio of 2.25 indicates that BMGL has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 2.25, BMGL is in the better half of the industry, outperforming 79.41% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.26
Quick Ratio 2.25
BMGL Yearly Current Assets VS Current LiabilitesBMGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 2024 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

BMGL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.25%, which is quite good.
The Revenue has been growing slightly by 3.60% in the past year.
EPS 1Y (TTM)16.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.25%
Revenue 1Y (TTM)3.6%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3.6%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
BMGL Yearly Revenue VS EstimatesBMGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 38.44 indicates a quite expensive valuation of BMGL.
BMGL's Price/Earnings is on the same level as the industry average.
BMGL's Price/Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 26.31.
Industry RankSector Rank
PE 38.44
Fwd PE N/A
BMGL Price Earnings VS Forward Price EarningsBMGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BMGL is on the same level as its industry peers.
BMGL's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 33.36
EV/EBITDA 16.75
BMGL Per share dataBMGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.1 0.2 0.3 0.4

4.3 Compensation for Growth

BMGL has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BMGL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BASEL MEDICAL GROUP LTD

NASDAQ:BMGL (6/13/2025, 8:00:02 PM)

After market: 3.76 +0.3 (+8.67%)

3.46

-1.24 (-26.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners13.65%
Ins Owner ChangeN/A
Market Cap65.01M
AnalystsN/A
Price TargetN/A
Short Float %4.78%
Short Ratio0.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 38.44
Fwd PE N/A
P/S 8.3
P/FCF 33.36
P/OCF 33.26
P/B 11.04
P/tB 11.04
EV/EBITDA 16.75
EPS(TTM)0.09
EY2.6%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.1
FCFY3%
OCF(TTM)0.1
OCFY3.01%
SpS0.42
BVpS0.31
TBVpS0.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 12.71%
ROE 27.41%
ROCE 48.37%
ROIC 31.78%
ROICexc 38.41%
ROICexgc 38.41%
OM 44.01%
PM (TTM) 20.62%
GM N/A
FCFM 24.89%
ROA(3y)12.01%
ROA(5y)N/A
ROE(3y)37.76%
ROE(5y)N/A
ROIC(3y)29.84%
ROIC(5y)N/A
ROICexc(3y)34.59%
ROICexc(5y)N/A
ROICexgc(3y)34.59%
ROICexgc(5y)N/A
ROCE(3y)47.14%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.62
Health
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF 1.71
Debt/EBITDA 0.86
Cap/Depr 1.49%
Cap/Sales 0.08%
Interest Coverage 25.11
Cash Conversion 50.67%
Profit Quality 120.68%
Current Ratio 2.26
Quick Ratio 2.25
Altman-Z 6.45
F-Score6
WACC8.53%
ROIC/WACC3.73
Cap/Depr(3y)5.99%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.32%
Cap/Sales(5y)N/A
Profit Quality(3y)134.28%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.25%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)3.6%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3.6%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-3.56%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.49%
OCF growth 3YN/A
OCF growth 5YN/A